Celgene (CELG)

Company Description

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.

 

COMPANY ADDRESS
86 Morris Avenue
Summit, NJ 07901
United States

COMPANY PHONE
908-673-9000

COMPANY WEBSITE



Get BioInvest's perspective on Celgene's CEO


Latest Company News

Trading Options During Earnings in Celgene Corporation (NASDAQ:CELG) CML News - 20 hours ago We're going to examine buying and selling out of the money strangles in Celgene Corporation and find out once and for all what the winning trades have been during earnings releases. [...]
Tue, Feb 21, 2017 4:28:00 PM, Continue reading at the source
Drilling Down Into Celgene Corporation (CELG) StockNewsJournal - Feb 20, 2017 Celgene Corporation (CELG) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $121.16, up from yesterday's close by 2.11%. [...]
Mon, Feb 20, 2017 3:45:00 PM, Continue reading at the source
Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands? Motley Fool - Feb 19, 2017 A new and highly anticipated study by Celgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. [...]
Sun, Feb 19, 2017 4:41:00 PM, Continue reading at the source
Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral ... Business Wire (press release) - Feb 17, 2017 SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with ... Celgene Higher Off Positive Phase II Sunbeam Trial Of Oral Ozanimod - Benzinga [...]
Fri, Feb 17, 2017 12:22:00 PM, Continue reading at the source
Celgene Corporation to Webcast at Upcoming Investor Conference Yahoo Finance - Feb 3, 2017 Celgene Corporation (CELG) plans to present at an upcoming investor conference where Celgene management will provide an overview of the Company. [...]
Fri, Feb 03, 2017 12:32:00 PM, Continue reading at the source
Should You Own Celgene In 2017? Part 6 Seeking Alpha - Feb 2, 2017 The previous articles of this series (see part 1, part 2, part 3, part 4, and part 5) have mainly focused on Celgene's (NASDAQ:CELG) existing product portfolio. What Could Make Biogen Crash? - Motley Fool [...]
Thu, Feb 02, 2017 2:37:00 PM, Continue reading at the source
Should You Own Celgene In 2017? Part 5 Seeking Alpha - Feb 1, 2017 Celgene's leading immunology and inflammation drug, Otezla, managed to cross the $1 billion mark within two years after its commercial launch. [...]
Wed, Feb 01, 2017 9:11:00 PM, Continue reading at the source
Celgene Corporation Continues Its Double-Digit Growth Motley Fool - Jan 27, 2017 Celgene's (NASDAQ:CELG) earnings release on Thursday didn't come with many surprises since the company announced preliminary fourth-quarter results earlier this month as it usually does at the annual J.P. Celgene Looks Cheap Right Now - Seeking Alpha [...]
Fri, Jan 27, 2017 6:20:00 PM, Continue reading at the source
Celgene Corporation Announces 34% Increase In Q4 Bottom Line Nasdaq - Jan 26, 2017 (RTTNews.com) - Celgene Corporation ( CELG ) reported a profit for its fourth quarter that advanced from last year. The company said its bottom line came in at $1.29 billion, or $1.61 per share. [...]
Thu, Jan 26, 2017 12:33:00 PM, Continue reading at the source
Earnings Reaction History: Celgene Corporation, 54.5% Follow-Through Indicator ... Nasdaq - Jan 26, 2017 Celgene Corporation ( CELG ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings announcement ... [...]
Thu, Jan 26, 2017 11:26:00 AM, Continue reading at the source